trending Market Intelligence /marketintelligence/en/news-insights/trending/ayu1x937aoo4rppj37chfg2 content esgSubNav
In This List

ATyr Pharma director forgoes re-election

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


ATyr Pharma director forgoes re-election

Srinivas Akkaraju decided not to stand for re-election as a director after completing his term at aTyr Pharma Inc.'s 2018 annual meeting of stockholders on May 15.

Akkaraju's decision not to stand for re-election was not a result of a disagreement with management regarding the company's operations, policies, practices or otherwise, according to ATyr Pharma.

San Diego, Calif.-based aTyr Pharma is a clinical stage biotherapeutics company, which engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases.